Dominari (DOMH) Competitors $5.74 +0.14 (+2.50%) As of 08/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. VNDA, CBIO, CDXS, AGEN, IRWD, SGMO, ACHV, FBIO, SABS, and CRISShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), Codexis (CDXS), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Dominari vs. Its Competitors Vanda Pharmaceuticals Crescent Biopharma Codexis Agenus Ironwood Pharmaceuticals Sangamo Therapeutics Achieve Life Sciences Fortress Biotech SAB Biotherapeutics Curis Dominari (NASDAQ:DOMH) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment. Which has more risk & volatility, DOMH or VNDA? Dominari has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Does the media favor DOMH or VNDA? In the previous week, Vanda Pharmaceuticals had 7 more articles in the media than Dominari. MarketBeat recorded 7 mentions for Vanda Pharmaceuticals and 0 mentions for Dominari. Dominari's average media sentiment score of 0.37 beat Vanda Pharmaceuticals' score of -0.06 indicating that Dominari is being referred to more favorably in the media. Company Overall Sentiment Dominari Neutral Vanda Pharmaceuticals Neutral Which has better valuation and earnings, DOMH or VNDA? Dominari has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$24.89M3.38-$14.70M-$4.50-1.28Vanda Pharmaceuticals$203.47M1.22-$18.90M-$1.13-3.72 Is DOMH or VNDA more profitable? Vanda Pharmaceuticals has a net margin of -32.90% compared to Dominari's net margin of -167.73%. Vanda Pharmaceuticals' return on equity of -12.89% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-167.73% -91.67% -77.80% Vanda Pharmaceuticals -32.90%-12.89%-10.47% Do analysts recommend DOMH or VNDA? Vanda Pharmaceuticals has a consensus price target of $16.50, suggesting a potential upside of 292.86%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals have more ownership in DOMH or VNDA? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 33.0% of Dominari shares are owned by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryVanda Pharmaceuticals beats Dominari on 12 of the 17 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.01M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.18%P/E Ratio-1.2819.6629.8725.14Price / Sales3.38634.80422.9397.17Price / CashN/A165.0335.9458.58Price / Book1.014.198.105.59Net Income-$14.70M$31.61M$3.26B$265.48M7 Day Performance27.56%0.95%0.64%1.22%1 Month Performance13.89%2.90%2.42%0.39%1 Year Performance272.73%4.11%27.60%23.47% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.6053 of 5 stars$5.74+2.5%N/A+267.9%$82.01M$24.89M-1.284News CoveragePositive NewsVNDAVanda Pharmaceuticals4.284 of 5 stars$4.72+0.3%$16.50+249.9%-19.2%$277.86M$198.77M-6.29290CBIOCrescent Biopharma3.0024 of 5 stars$13.01-1.8%$25.67+97.3%N/A$254.35MN/A-0.2850CDXSCodexis3.7946 of 5 stars$2.90-4.8%$11.00+280.0%-7.9%$239.84M$49.82M-2.92250News CoveragePositive NewsAGENAgenus4.2092 of 5 stars$5.96-6.1%$16.33+174.0%-6.3%$163.42M$103.46M-0.69440Upcoming EarningsIRWDIronwood Pharmaceuticals4.481 of 5 stars$0.90+12.2%$4.78+433.9%-85.4%$145.31M$351.41M-4.49220News CoverageEarnings ReportUpcoming EarningsGap UpSGMOSangamo Therapeutics2.1809 of 5 stars$0.58-3.7%$4.50+678.5%-43.7%$134.77M$63.76M-1.48480News CoverageEarnings ReportGap DownACHVAchieve Life Sciences1.9589 of 5 stars$2.62-2.8%$14.33+448.1%-40.1%$90.71MN/A-1.9520News CoverageEarnings ReportFBIOFortress Biotech2.203 of 5 stars$1.90-4.3%$21.00+1,008.2%+6.9%$56.04M$57.67M-0.85170Upcoming EarningsSABSSAB Biotherapeutics3.0481 of 5 stars$2.43-4.2%$13.00+436.1%-15.8%$22.53M$1.32M-0.66140News CoverageEarnings ReportGap DownCRISCuris2.1867 of 5 stars$1.77-3.0%$17.00+863.2%-61.1%$18.46M$10.91M-0.2860Positive NewsEarnings ReportShort Interest ↑ Related Companies and Tools Related Companies Vanda Pharmaceuticals Competitors Crescent Biopharma Competitors Codexis Competitors Agenus Competitors Ironwood Pharmaceuticals Competitors Sangamo Therapeutics Competitors Achieve Life Sciences Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DOMH Stock Alerts